# Progress Note 04 — Focused Visit (Care-plan review)

> **SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD**

- Patient: Ann Richards (real historical name used in a fictional teaching record)
- Synthetic MRN: HR-ML019-SYN-TD
- Date: 1997-08-11
- Fictional facility: St. Posthumous Health Center
- Fictional author: Rosalind Teague, MD
- Calendar frame: true historical dates (modern content is anachronistic)

> True-date frame: synthetic events are moved into the patient's historical lifetime. Codes, instruments, and treatments remain modern and are anachronistic.

- Visit type: Focused Visit (Care-plan review)

## Chief complaint

Six-month bone health review, three months after the first zoledronic acid infusion. **S**

## History of present illness

Ms. Richards returns three months after her first zoledronic acid infusion. The evening after the infusion she had aching muscles and a temperature of 37.9 °C, which settled with acetaminophen and were gone on the third day; she has had no symptoms since. She has had no muscle cramps, tingling, jaw pain, or thigh or groin pain. She takes vitamin D3 1971 units a day and keeps her calcium at about 1200 mg a day from food. She does the home balance program three times a week, walks most days, and has had no falls. She came fasting this morning for her blood tests. She has had no alcohol. **S**

| Element | Detail |
|---|---|
| Infusion reaction | Aches and 37.9 °C for two days after the dose, settled with acetaminophen |
| Drug safety | No cramps, tingling, jaw pain, or thigh or groin pain |
| Supplements and diet | D3 1971 units daily; calcium about 1200 mg a day from food |
| Falls | None; home balance program three times a week |
| Recovery | No alcohol; no cravings |

## Review of systems

| System | Result | Finding |
|---|---|---|
| Constitutional | Negative | No fever or fatigue since the third day after the infusion |
| Musculoskeletal | Negative | No bone, thigh, or groin pain; no muscle cramps |
| Ears, nose, mouth, and throat | Negative | No jaw pain, loose teeth, or mouth sores |
| Eyes | Negative | No eye pain or redness |
| Psychiatric | Negative | Mood good; no cravings; no thoughts of self-harm |

5 systems reviewed. **S**

## Current medications

- Cholecalciferol (vitamin D3) 50 mcg (1971 units) oral tablet, one tablet daily **S**
- Zoledronic acid 5 mg in 100 mL intravenous infusion over 30 minutes, once every 12 months **S**

## Allergies

- No known allergy **S**

## Objective

BP 122/76 mmHg; pulse 68 bpm; respirations 14/min; temperature 36.7 °C; oxygen saturation 98% on room air; weight 66 kg; BMI 24.5 kg/m². All vital signs are synthetic.

Serum CTX (fasting morning sample): 190 pg/mL; Calcium: 9.3 mg/dL. All results are synthetic.

## Change since baseline

- Serum CTX (fasting morning sample): 560 pg/mL at baseline, 190 pg/mL at this visit **S**
- Calcium: 9.4 mg/dL at baseline, 9.3 mg/dL at this visit **S**

## Physical examination

| System | Finding |
|---|---|
| General | Well; weight 66.0 kg |
| Mouth | No exposed bone or gum swelling |
| Musculoskeletal | No thigh tenderness; full painless hip movement |
| Gait and balance | Timed Up and Go 9 seconds; tandem stance 20 seconds |

All examination findings are synthetic. **S**

## Assessment and plan

1. **Low bone mass with high fracture risk, on zoledronic acid** (M85.89). Fasting CTX 190 pg/mL, 66 percent lower than the baseline of 560, showing the expected response. Calcium 9.3 mg/dL. The acute-phase reaction after the first dose was mild and brief and usually does not recur with later doses. No signs of osteonecrosis of the jaw or atypical femoral fracture. **S**
   - Continue vitamin D3 1971 units daily and calcium from food.
   - Second yearly dose in May after calcium, creatinine, and 25-hydroxyvitamin D.
   - DXA two years after starting; reassess for a drug holiday after the third yearly dose.
2. **History of falls** (Z91.81). No falls in six months; balance gains kept up with the home program. **S**
   - Continue the home balance and strength program.
3. **Alcohol use disorder in sustained remission** (F10.21). No alcohol or cravings. Safety reviewed: no thoughts of suicide or self-harm; the 988 Suicide & Crisis Lifeline is saved in her phone. **S**
   - Continue the recovery check at each visit.

## Protocol monitoring

Items the monitoring protocol calls for at this visit. **S**

| Domain | Measure | Interval | Status | Detail |
|---|---|---|---|---|
| Laboratory | Bone-turnover marker (fasting serum CTX) | Baseline, then 3 to 6 months after starting or changing therapy | Completed today | 190 pg/mL, 66 percent below the baseline of 560; response and adherence confirmed |
| Laboratory | Serum calcium | Before each zoledronic acid dose, and after the first dose if symptoms suggest hypocalcemia | Completed today | 9.3 mg/dL, normal; checked with the CTX sample |
| Laboratory | 25-hydroxyvitamin D | After repletion until 30 ng/mL or more; then yearly | Up to date | 38 ng/mL in May; next with the pre-infusion tests in May |
| Medication safety | Acute-phase reaction after zoledronic acid | After the first dose | Completed today | Aches and 37.9 °C for two days, settled with acetaminophen; acetaminophen offered again for the next dose |
| Medication safety | Osteonecrosis of the jaw and atypical femoral fracture symptoms | At each visit on antiresorptive therapy | Completed today | No jaw pain or exposed bone; no thigh or groin pain; routine dental care twice a year |
| Imaging | Central DXA of the spine and hip | Every 1 to 2 years on therapy until stable, on the same scanner | Up to date | Due two years after starting therapy, on the same scanner |
| Examination | Standing height by stadiometer | Yearly; vertebral imaging again if height falls 2 cm or more | Up to date | 164.0 cm, unchanged |
| Examination | Fall-risk screen | Yearly, and with any fall | Completed today | Timed Up and Go 9 seconds, tandem stance 20 seconds; no falls |
| Survey | FRAX 10-year fracture risk | At baseline, when risk factors change, and at the drug-holiday decision | Up to date | No change in risk factors; next at the drug-holiday decision |
| Survey | Calcium intake assessment | At baseline and yearly | Up to date | About 1200 mg a day from food |
| Medication safety | Drug-holiday eligibility | After 3 yearly zoledronic acid doses or 5 years of an oral bisphosphonate | Not indicated | One dose so far; reassess after the third yearly dose |
| Self-management | Balance and strength exercise program | With a history of falls or impaired balance | Up to date | Home program three times a week |
| Self-management | Recovery check (alcohol, cravings, stress) | Every visit | Completed today | No alcohol; no cravings |
| Survey | Suicide-risk review and safety plan, with the 988 Suicide & Crisis Lifeline | Every visit | Completed today | No thoughts of suicide or self-harm; the 988 Suicide & Crisis Lifeline is saved in her phone |

## Goal progress

- Total calcium intake of about 1200 mg a day, mostly from food, by the four-week visit. Outcome by 1997-03-10: About 1200 mg a day from food by her own three-day food record. **S**
- 25-hydroxyvitamin D of 30 ng/mL or more before the first infusion. Outcome by 1997-05-12: 24 ng/mL at intake and 38 ng/mL at three months. **S**
- First zoledronic acid dose by the three-month visit, with normal calcium and kidney function and a dental check done. Outcome by 1997-05-12: Given at three months after normal calcium (9.5 mg/dL) and eGFR (81) and a routine dental examination. **S**
- Complete the eight-week balance and strength program, with no falls through six months. Outcome by 1997-08-11: 16 of 16 sessions; Timed Up and Go 9 seconds and tandem stance 20 seconds at six months; no falls. **S**
- Serum CTX at least 30 percent lower three months after the first dose. Outcome by 1997-08-11: 560 pg/mL at baseline and 190 pg/mL at three months after the dose (66 percent lower). **S**
- Sustained remission from alcohol use disorder throughout the episode. Outcome by 1997-08-11: No alcohol reported at any visit; AUDIT-C 0 at intake. **S**

## Guideline basis

- CMID: Clinical Monitoring Intelligence Database, osteoporosis monograph (2026), Aether Forge
- The clinician's guide to prevention and treatment of osteoporosis (2022), Bone Health and Osteoporosis Foundation (LeBoff MS et al., Osteoporos Int 2022;33(10):2049-2102)
- American Association of Clinical Endocrinologists/American College of Endocrinology Clinical Practice Guidelines for the Diagnosis and Treatment of Postmenopausal Osteoporosis, 2020 Update (2020), AACE/ACE (Camacho PM et al., Endocr Pract 2020;26(Suppl 1):1-46)
- Pharmacological Management of Osteoporosis in Postmenopausal Women: An Endocrine Society Clinical Practice Guideline (2019), Endocrine Society (Eastell R et al., J Clin Endocrinol Metab 2019;104(5):1595-1622)
- STEADI: Stopping Elderly Accidents, Deaths, and Injuries (2026), Centers for Disease Control and Prevention
- VA/DoD Clinical Practice Guideline for the Management of Substance Use Disorders (2021), United States Department of Veterans Affairs and Department of Defense
- VA/DoD Clinical Practice Guideline for Assessment and Management of Patients at Risk for Suicide (2024), United States Department of Veterans Affairs and Department of Defense

## Follow-up

- Adult preventive visit in October. Second zoledronic acid dose in May with pre-infusion tests. Call for jaw pain, thigh or groin pain, or any fall. **S**
- Next scheduled visit 1997-10-06: adult preventive visit. **S**
